Fourniture de médicaments radiopharmaceutiques
AI summary
This tender concerns the supply of radiopharmaceutical medicines, specifically a fluorinated tracer targeting prostate-specific membrane antigen (PSMA). The product is used for initial staging of patients with high-risk prostate cancer before curative treatment and for detecting prostate cancer recurrence in patients with suspected recurrence based on elevated PSA levels.
Radiopharmaceutical manufacturers or authorized distributors specializing in nuclear medicine products and capable of supplying hospital establishments in France.
Suppliers must be capable of providing radiopharmaceutical products meeting hospital pharmaceutical standards and regulatory requirements. Experience in nuclear medicine radiopharmaceuticals and compliance with French health authority regulations is essential.
Frequently asked questions
What is this tender about?
This tender concerns the supply of radiopharmaceutical medicines, specifically a fluorinated tracer targeting prostate-specific membrane antigen (PSMA). The product is used for initial staging of patients with high-risk prostate cancer before curative treatment and for detecting prostate cancer recurrence in patients with suspected recurrence based on elevated PSA levels.
What are the requirements for suppliers?
Suppliers must be capable of providing radiopharmaceutical products meeting hospital pharmaceutical standards and regulatory requirements. Experience in nuclear medicine radiopharmaceuticals and compliance with French health authority regulations is essential.
What type of company should bid?
Radiopharmaceutical manufacturers or authorized distributors specializing in nuclear medicine products and capable of supplying hospital establishments in France.
Who is the buyer?
The buyer is Centre Hospitalier Alpes Léman (établissement support du GHT Léman Mont-Blanc).
When does this tender close?
Submissions close on June 10, 2026.
Fourniture de médicaments radiopharmaceutiques Traceur fluoré spécifique de l'antigène membranaire spécifique de la prostate permettant la stadification initiale des patients présentant un cancer prostatique à haut risque avant un traitement initial à visée curative ET la localisation de récidive du cancer de la prostate, chez les patients présentant une suspicion de récidive basée sur l’augmentation des concentrations sériques d’antigène prostatique spécifique (PSA) après un traitement initial à visée curative
Fourniture de médicaments radiopharmaceutiques
Fourniture de médicaments radiopharmaceutiques Traceur fluoré spécifique de l'antigène membranaire spécifique de la prostate permettant la stadification initiale des patients présentant un cancer prostatique à haut risque avant un traitement initial à visée curative ET la localisation de récidive du cancer de la prostate, chez les patients présentant une suspicion de récidive basée sur l’augmentation des concentrations sériques d’antigène prostatique spécifique (PSA) après un traitement initial à visée curative
Scoring criteria not specified
Computing match…
AI document analysis
We read the tender PDFs and DOCX files and surface key requirements, deadlines, budget and red flags.
Loading…